Focus on repaglinide: An oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas

Formulary

Volumn 33, Issue 5, 1998, Pages 409-423

  Wang, Fei ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PLACEBO; REPAGLINIDE; RIFAMPICIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

AREA UNDER THE CURVE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; REVIEW; UPPER RESPIRATORY TRACT INFECTION;

EID: 0032431635     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. Graul A, Castañer J. Repaglinide. Drugs of the Future 1996;21:694-9.
3. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family. Horm Metab Res 1995;27:263-6.
4. Wolffenbuttel BUR, Nijst L, Sels JPJE, et al. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993;45:113-6.
5. Parentesis GP, Damsbo P, Müller PG, et al. Single dose pharmacokinetics and pharmacodynamics of repaglinide in type II diabetic patients (abstract No. 56). J Clin Pharmacol 1994;34:1021.
6. Ampudia-Blasco FJ, Heinemann L, Bender R, et al. Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects. Diabetologia 1994;37:703-7.
7. Van Onderbergen A, Malaisse-Lagae F, Malaisse WJ. Failure of meglitinide analogues to augment Ba2+ induced insulin release. Med Sci Res 1995;23:371-2.
8. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes 1996;104:1-9.
9. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in β TC3 cells and rat pancreatic beta cells. Diabetologia 1995;38:1025-32.
10. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-47.
11. Kofod H, Fuhlendorff J. Repaglinide compared to glibenclamide in isolated mouse islets by perifusion (abstract No. 753). Diabetologia 1995;38 (Suppl 1):A195.
12. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Insulinotropic action of meglitinide analogs: Concentration-response relationship and nutrient dependency. Diabetes Res 1994;27:81-7.
13. Frokjaer-Jensen J, Kofod H, Godtfredsen SE. Mechanism of action of AG-EE 623 ZW, a novel insulinotropic agent (abstract No. 447). Diabetologia 1992;35(Suppl 1):A116.